Nuclear power is gaining renewed interest due to increasing electricity demand from advances in AI. Centrus Energy plays a critical role in the nuclear supply chain, providing low-enriched uranium and advanced uranium enrichment services.
Centrus Energy slips 11% after Q3 miss, but its 333.9% YTD surge and HALEU expansion plans keep its long-term story strong.
Centrus Energy Corp. (LEU) came out with quarterly earnings of $0.19 per share, missing the Zacks Consensus Estimate of $0.2 per share. This compares to a loss of $0.3 per share a year ago.
Centrus Energy gears up for Q3 results with revenues up 32% and a profit rebound expected, though an earnings beat remains unclear.
As nuclear demand surges worldwide, Centrus Energy and Cameco stand out, but Centrus' HALEU edge makes it the brighter investment bet.
LEU's 1H25 revenues dip 2% as weak uranium sales offset solid gains in its Technical segment.
Centrus Energy is the only U.S. company licensed to produce next-gen nuclear fuel (HALEU), positioning it for significant future growth. LEU's unique regulatory position and anticipated HALEU demand could drive dramatic revenue and profit expansion over the next decade. Despite strong long-term prospects, LEU trades at a steep valuation (80x earnings), with meaningful growth not expected until the 2030s.
Centrus Energy (LEU) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Centrus Energy stands out with exclusive HALEU production rights, a strong backlog and better valuation compared with Uranium Energy.
Centrus Energy and Energy Fuels face diverging growth paths as nuclear demand rises, with LEU gaining an edge on estimates and valuation.
Centrus is the only listed U.S. supplier of enriched uranium, with a $3.6B backlog and $833M cash, giving visibility and financing flexibility. Revenue fell to $154.5M (down $34.5M YoY) due to lower SWU sales, but gross margin jumped to 35% and net income held steady at $28.9M. $60M investment in supply chain readiness, DOE contract extension for HALEU through 2026 (with option to 2034), and nearly one ton of HALEU already produced.
LEU's weak uranium sales drag Q2 results, but a $3.6B backlog underscores long-term strength despite near-term headwinds.